New marker may be more specific for prostate cancer

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

In this episode, Janelle Bunce, PA-C, highlights the role that advanced practice providers can play in filling the gaps created by the growing workforce shortages in urology.

The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.

"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.

Dr. Kate Meriwether, AUGS Publications Committee member, interviews Dr Colleen McDermott, the first author of the Clinical Consensus Statement “Postoperative Urinary Retention,” to provide an overview and highlight the findings of the document.

AUGS is seeking both interested mentors and mentees who are looking for a mutually rewarding mentorship experience.